Dermtech Stock Today
| DMTK Stock | USD 0.61 0.01 0.97% |
Performance0 of 100
| Odds Of DistressOver 84
|
DermTech is selling for 0.614 as of the 25th of April 2024. This is a -0.97 percent decrease since the beginning of the trading day. The stock's last reported lowest price was 0.58. DermTech has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. Equity ratings for DermTech are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 6th of May 2022 and ending today, the 25th of April 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 10th of August 2017 | Category Healthcare | Classification Health Care |
DermTech, Inc., a molecular diagnostic company, develops and markets novel non-invasive genomics tests to diagnosis skin cancer, inflammatory diseases, and aging-related conditions in the United States. The company sells its products primarily to pathology and oncology practitioners. The company has 34.62 M outstanding shares of which 3.16 M shares are currently shorted by private and institutional investors with about 6.32 trading days to cover. More on DermTech
Moving against DermTech Stock
| 0.86 | ELEV | Elevation Oncology Earnings Call This Week | PairCorr |
| 0.75 | VKTX | Viking Therapeutics Potential Growth | PairCorr |
| 0.73 | NRSNW | NeuroSense Therapeutics | PairCorr |
| 0.7 | XFOR | X4 Pharmaceuticals Earnings Call This Week | PairCorr |
| 0.54 | CGC | Canopy Growth Corp Trending | PairCorr |
| 0.53 | LLY | Eli Lilly Earnings Call This Week | PairCorr |
| 0.5 | BMY | Bristol Myers Squibb Earnings Call Today | PairCorr |
DermTech Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. DermTech's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding DermTech or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| CEO President | Bret Christensen | |||||||||||||||||||||||||||||||||||||||||||||
| Thematic Idea | Healthcare (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Healthcare, Health Care, Biotechnology, Diagnostics & Research, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation Analysts covering DermTech report their recommendations after researching DermTech's financial statements, talking to executives and customers, or listening in on DermTech's conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering DermTech. The DermTech consensus assessment is calculated by taking the average forecast from all of the analysts covering DermTech. | ||||||||||||||||||||||||||||||||||||||||||||||
| Financial Strength Based on the key indicators obtained from DermTech's historical financial statements, DermTech is not in a good financial situation at this time. It has a very high odds of going through financial crisis in May. Financial strength of DermTech is based on its profitability, leverage, liquidity, source of funds, and operating efficiency.
| ||||||||||||||||||||||||||||||||||||||||||||||
DermTech's financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to DermTech's success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. | ||||||||||||||||||||||||||||||||||||||||||||||
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand DermTech's financial leverage. It provides some insight into what part of DermTech's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||
DermTech (DMTK) is traded on NASDAQ Exchange in USA. It is located in 12340 El Camino Real, San Diego, CA, United States, 92130 and employs 206 people. DermTech is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 21.33 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate DermTech's market, we take the total number of its shares issued and multiply it by DermTech's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. DermTech conducts business under Biotechnology sector and is part of Health Care industry. The entity has 34.62 M outstanding shares of which 3.16 M shares are currently shorted by private and institutional investors with about 6.32 trading days to cover.
DermTech currently holds about 173.79 M in cash with (76.98 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.78, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check DermTech Probability Of Bankruptcy
Ownership AllocationDermTech holds a total of 34.62 Million outstanding shares. DermTech shows 4.24 percent of its outstanding shares held by insiders and 21.08 percent owned by other corporate entities. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check DermTech Ownership Details
DermTech Stock Price Odds Analysis
Proceeding from a normal probability distribution, the odds of DermTech jumping above the current price in 90 days from now is about 85.65%. The DermTech probability density function shows the probability of DermTech stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days the stock has a beta coefficient of 1.6574 suggesting as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, DermTech will likely underperform. Additionally, dermTech has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the NYSE Composite.
Based on a normal probability distribution, the odds of DermTech to move above the current price in 90 days from now is about 85.65 (This DermTech probability density function shows the probability of DermTech Stock to fall within a particular range of prices over 90 days) .
DermTech Stock Institutional Holders
Institutional Holdings refers to the ownership stake in DermTech that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of DermTech's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing DermTech's value.| Instituion | Recorded On | Shares | |
| Susquehanna International Group, Llp | 2023-12-31 | 85.7 K | |
| Woodmont Investment Counsel Llc | 2023-12-31 | 84.2 K | |
| Northern Trust Corp | 2023-12-31 | 77.5 K | |
| Bank Of New York Mellon Corp | 2023-12-31 | 75.2 K | |
| Jane Street Group, Llc | 2023-12-31 | 74.8 K | |
| State Treasurer State Of Michigan | 2023-12-31 | 60 K | |
| Advisor Group Holdings, Inc. | 2023-12-31 | 59.3 K | |
| Marshall Wace Asset Management Ltd | 2023-12-31 | 57.6 K | |
| Virtu Financial Llc | 2023-12-31 | 55.2 K | |
| Vanguard Group Inc | 2023-12-31 | 1.4 M | |
| Blackrock Inc | 2023-12-31 | 434.9 K |
DermTech Historical Income Statement
DermTech Income Statement is one of the three primary financial statements used for reporting DermTech's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of DermTech revenue and expense. DermTech Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At this time, DermTech's Cost Of Revenue is quite stable compared to the past year. Total Operating Expenses is expected to rise to about 109.2 M this year, although the value of EBIT is projected to rise to (98.6 M). View More FundamentalsDermTech Stock Against Markets
Picking the right benchmark for DermTech stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in DermTech stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for DermTech is critical whether you are bullish or bearish towards DermTech at a given time. Please also check how DermTech's historical prices are related to one of the top price index indicators.
Be your own money manager
Our tools can tell you how much better you can do entering a position in DermTech without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Global Markets Map Now
Global Markets MapGet a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes |
| All Next | Launch Module |
DermTech Corporate Management
Elected by the shareholders, the DermTech's board of directors comprises two types of representatives: DermTech inside directors who are chosen from within the company, and outside directors, selected externally and held independent of DermTech. The board's role is to monitor DermTech's management team and ensure that shareholders' interests are well served. DermTech's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, DermTech's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Kevin MBA | Treasurer CFO | Profile | |
| Burkhard MD | Chief Officer | Profile | |
| Todd Wood | Chief Officer | Profile | |
| Daniel Visage | Senior Access | Profile | |
| Steven Stone | Senior Development | Profile | |
| Loren MD | Chief Officer | Profile | |
| JD Esq | General Counsel | Profile |
How to buy DermTech Stock?
Before investing in DermTech, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in DermTech. To buy DermTech stock, you can follow these steps:- Choose a brokerage firm: You need to select a brokerage firm to buy shares of DermTech. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
- Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
- Fund your account: You will need to deposit funds into your brokerage account to purchase DermTech stock. You can do this by transferring funds from your bank account or other investment accounts.
- Place your order: Once you have located DermTech stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
- Monitor your investment: After you have purchased DermTech stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as DermTech, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. For more information on how to buy DermTech Stock please use our How to Invest in DermTech guide.
Already Invested in DermTech?
The danger of trading DermTech is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of DermTech is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than DermTech. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile DermTech is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether DermTech is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if DermTech Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Dermtech Stock. Highlighted below are key reports to facilitate an investment decision about Dermtech Stock: Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in DermTech. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. For more information on how to buy DermTech Stock please use our How to buy in DermTech Stock guide.You can also try the Top Crypto Exchanges module to search and analyze digital assets across top global cryptocurrency exchanges.
Complementary Tools for DermTech Stock analysis
When running DermTech's price analysis, check to measure DermTech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy DermTech is operating at the current time. Most of DermTech's value examination focuses on studying past and present price action to predict the probability of DermTech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move DermTech's price. Additionally, you may evaluate how the addition of DermTech to your portfolios can decrease your overall portfolio volatility.
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk |
Is DermTech's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of DermTech. If investors know DermTech will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about DermTech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.09) | Revenue Per Share 0.469 | Quarterly Revenue Growth 0.311 | Return On Assets (0.38) | Return On Equity (1.06) |
The market value of DermTech is measured differently than its book value, which is the value of DermTech that is recorded on the company's balance sheet. Investors also form their own opinion of DermTech's value that differs from its market value or its book value, called intrinsic value, which is DermTech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because DermTech's market value can be influenced by many factors that don't directly affect DermTech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between DermTech's value and its price as these two are different measures arrived at by different means. Investors typically determine if DermTech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, DermTech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.